| Name | Title | Contact Details |
|---|
At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.
ReviveRX is a leading licensed mail-order pharmacy specializing in generic and compounded medications. Our compounds are expertly crafted in USP-certified clean rooms at our Houston headquarters, ensuring the highest quality standards. We work closely with best-in-class pharmacists, scientists, healthcare providers, and pharmaceutical manufacturers to provide high-quality, dependable products to our patients and clinic partners.
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.